findmyKOL
Clinical trialNCT04506554Active, not recruitingPhase 2Interventional

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

SponsorFox Chase Cancer CenterEnrollment81Muscle-Invasive Bladder Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserve their bladders and go on active surveillance.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

  • Fox Chase Cancer Center - Philadelphia

    Philadelphia, Pennsylvania, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, United States

  • Ut Southwestern Medical Center

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AMVAC + Nivolumab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Dec 2020
Primary completion
31 May 2026
Completion
30 Nov 2028
Last update posted
4 Jul 2025
Registered enrollment
81
Registry id
NCT04506554
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.